Literature DB >> 26091295

Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.

Enju Liu1, Abel Makubi, Paul Drain, Donna Spiegelman, David Sando, Nan Li, Guerino Chalamilla, Christopher R Sudfeld, Ellen Hertzmark, Wafaie W Fawzi.   

Abstract

OBJECTIVE: The objective of this study is to determine the incidence rate and risk factors of tuberculosis (TB) among HIV-infected adults accessing antiretroviral therapy (ART) in Tanzania.
DESIGN: A prospective observational study among HIV-infected adults attending HIV clinics in Dar es Salaam.
METHODS: We estimated TB incidence rates among HIV-infected patients prior to and after ART initiation. We used Cox proportional hazard regressions to determine the predictors of incident TB among HIV-infected adults enrolled in the HIV care and treatment programme.
RESULTS: We assessed 67 686 patients for a median follow-up period of 24 (interquartile range: 8-49) months; 7602 patients were diagnosed with active TB. The TB incidence rate was 7.9 [95% confidence interval (95% CI), 7.6-8.2] per 100 person-years prior to ART initiation, and 4.4 (95% CI, 4.2-4.4) per 100 person-years for patients receiving ART. In multivariate analyses, patients on ART in the first 3 months had a 57% higher risk of TB (hazard ratio: 1.57, 95% CI, 1.47-1.68) than those not on ART, but the risk significantly decreased with increasing duration of ART. Risk factors for incident TB included being male, having low BMI or middle upper arm circumference, lower CD4 cell count and advanced WHO disease stage. There was seasonal variation for incident TB, with higher risk observed following the rainy seasons (May, June and November).
CONCLUSION: In TB endemic regions, HIV-infected patients initiating ART, particularly men and those with poor nutritional status, should be closely monitored for active TB at ART initiation. In addition to increasing the access to ART, interventions should be considered to improve nutritional status among HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091295      PMCID: PMC4576970          DOI: 10.1097/QAD.0000000000000705

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania.

Authors:  Enju Liu; Donna Spiegelman; Helen Semu; Claudia Hawkins; Guerino Chalamilla; Akum Aveika; Stella Nyamsangia; Saurabh Mehta; Deo Mtasiwa; Wafaie Fawzi
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

3.  Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy.

Authors:  Stephen D Lawn; Katharina Kranzer; David J Edwards; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.

Authors:  E Martín-Echevarria; S Serrano-Villar; T Sainz; A Moreno; J L Casado; F Dronda; M J Pérez Elías; E Navas; M Rodríguez Zapata; S Moreno
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

5.  Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study.

Authors:  R J Wilkinson; M Llewelyn; Z Toossi; P Patel; G Pasvol; A Lalvani; D Wright; M Latif; R N Davidson
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

Review 6.  Triple trouble: the role of malnutrition in tuberculosis and human immunodeficiency virus co-infection.

Authors:  Monique van Lettow; Wafaie W Fawzi; Richard D Semba
Journal:  Nutr Rev       Date:  2003-03       Impact factor: 7.110

7.  Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.

Authors:  Maxwell O Akanbi; Chad J Achenbach; Joe Feinglass; Babafemi Taiwo; Adamu Onu; Mai T Pho; Oche Agbaji; Phyllis Kanki; Robert L Murphy
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

8.  Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.

Authors:  William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders
Journal:  Clin Dev Immunol       Date:  2010-12-08

9.  Association between Gc genotype and susceptibility to TB is dependent on vitamin D status.

Authors:  A R Martineau; A C C S Leandro; S T Anderson; S M Newton; K A Wilkinson; M P Nicol; S M Pienaar; K H Skolimowska; M A Rocha; V C Rolla; M Levin; R N Davidson; S A Bremner; C J Griffiths; B S Eley; M G Bonecini-Almeida; R J Wilkinson
Journal:  Eur Respir J       Date:  2009-09-24       Impact factor: 16.671

Review 10.  Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Authors:  Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich
Journal:  PLoS Med       Date:  2012-07-24       Impact factor: 11.069

View more
  39 in total

1.  Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania.

Authors:  Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

2.  Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.

Authors:  J Morgan Freiman; Karen R Jacobson; Winnie R Muyindike; C Robert Horsburgh; Jerrold J Ellner; Judith A Hahn; Benjamin P Linas
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

3.  Drivers of Seasonal Variation in Tuberculosis Incidence: Insights from a Systematic Review and Mathematical Model.

Authors:  Christine Tedijanto; Sabine Hermans; Frank Cobelens; Robin Wood; Jason R Andrews
Journal:  Epidemiology       Date:  2018-11       Impact factor: 4.822

4.  The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Authors:  Ka Lai Yee; Sauzanne G Khalilieh; Rosa I Sanchez; Rachael Liu; Matt S Anderson; Helen Manthos; Timothy Judge; John Brejda; Joan R Butterton
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

5.  Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Authors:  Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

6.  Incidence and predictors of Tuberculosis among patients enrolled in Anti-Retroviral Therapy after universal test and treat program, Addis Ababa, Ethiopia. A retrospective follow -up study.

Authors:  Amare Getu; Haileab Fekadu Wolde; Yaregal Animut; Anteneh Ayelign Kibret
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

7.  Synergy between low BMI and hyperglycemia at baseline increases tuberculosis incidence among people living with HIV.

Authors:  Nang T T Kyaw; Ajay M V Kumar; Anthony D Harries; Srinath Satyanarayana; Nay L Oo; Matthew J Hayat; Kenneth G Castro; Matthew J Magee
Journal:  AIDS       Date:  2022-01-01       Impact factor: 4.177

8.  Predicting the risk of active pulmonary tuberculosis in people living with HIV: development and validation of a nomogram.

Authors:  Jinou Chen; Ling Li; Tao Chen; Xing Yang; Haohao Ru; Xia Li; Xinping Yang; Qi Xie; Lin Xu
Journal:  BMC Infect Dis       Date:  2022-04-19       Impact factor: 3.667

9.  Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria.

Authors:  Charlotte A Chang; Seema Thakore Meloni; Geoffrey Eisen; Beth Chaplin; Patrick Akande; Prosper Okonkwo; Holly E Rawizza; Eric Tchetgen Tchetgen; Phyllis J Kanki
Journal:  Open Forum Infect Dis       Date:  2015-10-17       Impact factor: 3.835

10.  Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana.

Authors:  Lucy Mupfumi; Sikhulile Moyo; Kesaobaka Molebatsi; Prisca K Thami; Motswedi Anderson; Tuelo Mogashoa; Thato Iketleng; Joseph Makhema; Richard Marlink; Ishmael Kasvosve; Max Essex; Rosemary M Musonda; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.